Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 31, Issue 9, 1996, Pages 928-933

  Moller S ^b   Bendtsen, F ^b   Schifter, S ^b   Henriksen, J H ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

Calcitonin gene related peptide; Central blood volume; Central circulation time; Cirrhosis; Hyperdynamic circulation; Peripheral vasodilatation; Portal hypertension; Systemic vascular resistance; Vasodilators

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOVOLEMIA; LIVER CIRRHOSIS; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0029787791     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609052004     Document Type: Article

References (46)

1. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
2. Schrier RW, Niederberger M, Weigert A, Gines P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Sem Liver Dis 1994;14:14-22.
3. Rector WG, Robertson AD, Lewis FW, Adair OV. Arterial underfilling does not cause sodium retention in cirrhosis. Am J Med 1993;95:286-95.
4. Levy M. Pathogensis of sodium retention in early cirrhosis of the liver: evidence for vascular overfilling. Sem Liver Dis 1994;14:4-13.
5. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-7.
6. Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989;97:1506-13.
7. Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TIA. Estimated central blood volume in cirrhosis - relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992;16:1163-70.
8. Groszmann RJ. Hyperdynamic state in chronic-liver diseases. J Hepatol 1993;17:S38-40.
9. Henriksen JH. Systemic haemodynamic alterations in hepatic cirrhosis. Eur J Gastroenterol Hepatol 1991;3:705-13.
10. Sherlock S. Vasodilatation associated with hepatocellular disease: relation to functional organ failure. Gut 1990;31:365-7.
11. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell, 1994:17-26.
12. Bosch J, Pizcueta MP, Fernandez M, Feu F, Cirera I, Luca A, et al. Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. In: Shields R, editor. Baillière's clinical gastroenterology. Portal hypertension. London: Baillière Tindall, 1992:425-36.
13. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-8.
14. Lee F-Y, Colombato LA, Albillos A, Groszmann RJ. N-nitro-L-arginine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
15. Claria J, Jimenez W, Ros J, Rigol M, Angeli P, Arroyo V, et al. Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology 1994;20:1615-21.
16. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993;104:1750-4.
17. Haussinger D. Nitric oxide and hyperdynamic circulation in portal hypertension. Hepatology 1992;16:1093-4.
18. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994;20: 1343-50.
19. Gupta S, Morgan TR, Gordan GS. Calcitonin gene-related peptide in hepatorenal syndrome. J Clin Gastroenterol 1992;14: 122-6.
20. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991;12:118-23.
21. O'Halloran DJ, Bloom SR. Calcitonin gene related peptide. A major neuropeptide and the most powerful vasodilator known. Br Med J 1991;302:739-40.
22. Gluud C, The Copenhagen Study Group for Liver Diseases. Serum testosterone concentration in men with alcoholic cirrhosis: background for variation. Metabolism 1987;36:373-8.
23. Henriksen JH, Ring-Larsen H, Kanstrup I-L, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with cirrhosis. Gut 1984;25:1034-43.
24. Larsen OA, Winkler K, Tygstrup N. Extra plasma in the liver calculated from the hepatic hematocrit in patients with portacaval anastomosis. Clin Sci 1963:25:357-60.
25. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver. Its relations to portal hypertension, ascites, and renal failure. J Clin Invest 1967;47:1297-308.
26. Henriksen JH, Ring-Larsen H, Christensen NJ. Circulating noradrenaline and central haemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985;20:1185-90.
27. Lassen NA, Perl W. Tracer kinetics methods in medical physiology. New York: Raven Press, 1979.
28. Tippins JR. CGRP: a novel neuropeptide from the calcitonin gene is the most potent vasodilator known. J Hypertension 1986;4 Suppl 5:S102-5.
29. Zaidi M, Breimer LH, Maclntyre I. Biology of peptides from the calcitonin genes. Q J Exp Physiol 1987;72:371-408.
30. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. Nature 1983;304:129-35.
31. Sasaki Y, Hayashi N, Kasahara A, Matsuda H, Fusamoto H, Sato N, et al. Calcitonin gene-related peptide in the hepatic and splanchnic vascular systems of the rat. Hepatology 1986;6: 676-81.
32. Struthers AD, Brown MJ, Macdonald DWR, Becham JL, Stevenson JC, Morris HR, et al. Human calcitonin gene-relatedpeptide: a potent endogenous vasodilator in man. Clin Sci 1986;70:389-93.
33. Struthers AD, Brown MJ, Beacham JL. The acute effect of human calcitonin gene-related peptide in man. J Endocrinol 1986;107S:129.
34. Rebello S, Roy S, Saxena PR, Gulati A. Systemic hemodynamic and regional circulatory effects of centrally administered endothelin-1 are mediated through ET(A) receptors. Brain Res 1995;676:141-50.
35. Matsumoto A, Ogura K, Hirata Y, Kakoki M, Watanahe F, Takenaka K, et al. Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 1995;123:110-13.
36. Sogni P, Gamier P, Gadano A, Moreau R, Dallavasantucci J, Dinhxuan AT, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995;23:471-3.
37. Campillo B, Chabrier PE, Pelle G, Sediame S, Atlan G, Fouet P, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995;22: 1423-9.
38. Cahill PA, Sitzmann JV. Nitric oxide and portal hypertension. J Hepatol 1995;23:355-6.
39. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-I and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-76.
40. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-7.
41. Lemoine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol 1995;23:391-5.
42. Murphy TC, Samson WK. The novel vasoactive hormone, adrenomedullin, inhibits water drinking in the rat. Endocrinology 1995;136:2459-63.
43. Kohno M, Kano H, Horio T, Yokokawa K, Yasunari K, Takeda T. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension 1995;25:1185-90.
44. Schell DA, Vari RC, Samson WK. Adrenomedullin: a newly discovered hormone controlling fluid and electrolyte homeostasis. Trends Endocrinol Metab 1996;7:7-13.
45. McNicol PL, Liu G, Shulkes A, Hardy KJ, Jones RM. Vasoactive intestinal peptide and calcitonin gene-related peptide levels and hemodynamics during human liver transplantation. Transplant Proc 1993;25:1830-1.
46. Møller S, Bendtsen F, Christensen E, Henriksen JH. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994;21:940-6.